We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-2.86%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.1B
AUM Growth
-$432M
Cap. Flow
+$36.5M
Cap. Flow %
3.32%
Top 10 Hldgs %
65.53%
Holding
227
New
63
Increased
36
Reduced
51
Closed
66

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$19.5M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$7.96M
3
MNKD icon
MannKind Corp
MNKD
+$4.94M
4
ESPR
Esperion Therapeutics
ESPR
+$3.17M
5
BNBX
BNB PLUS CORP
BNBX
+$2.81M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.35M
2
BMY icon
Bristol-Myers Squibb
BMY
+$3.2M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.96M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$2.32M
5
HURA
TuHURA Biosciences
HURA
+$1.78M

Sector Composition

Rank Sector Weight
1 Miscellaneous 86.88%
2 Healthcare 12.71%
3 Financials 0.19%
4 Technology 0.09%
5 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGLBW
126
DELISTED
Sigma Labs, Inc. Warrant
SGLBW
$184K 0.02%
382,868
+136,349
+55% +$60.9K
NUWE icon
127
Nuwellis
NUWE
$2.59M
– –
0
– –
JAGX icon
128
Jaguar Health
JAGX
$1.37M
– –
0
– –
ORKA
129
Oruka Therapeutics
ORKA
$6.11B
$138K 0.01%
463
– –
SPHS
130
DELISTED
Sophiris Bio, Inc.
SPHS
$127K 0.01%
55,907
-277,734
-83% -$605K
AIXC
131
AIxCrypto Holdings Inc
AIXC
$23.2M
$118K 0.01%
3
-34
-92% -$1.44M
RDHL
132
Redhill Biopharma
RDHL
$3.65M
$110K 0.01%
+21
New +$141K
ANTH
133
PUT
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$109K 0.01%
+658
New +$1.13K
AMRS
134
PUT
DELISTED
Amyris Inc.
AMRS
$94K 0.01%
+250
New +$842
ADXS
135
CALL
DELISTED
Advaxis Inc
ADXS
$77K 0.01%
18
– –
EGLT
136
DELISTED
Egalet Corporation
EGLT
$74K 0.01%
73,792
-647,258
-90% -$697K
TNDM icon
137
Tandem Diabetes Care
TNDM
$1.16B
$65K 0.01%
+27,487
New +$86.3K
SPHS
138
PUT
DELISTED
Sophiris Bio, Inc.
SPHS
$62K 0.01%
275
+163
+146% +$355
NBRV
139
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$60K 0.01%
+40
New +$63.3K
FCEL icon
140
PUT
FuelCell Energy
FCEL
$1.23B
$55K 0.01%
3
+2
+200% +$1.39K
ACHN
141
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$50K ﹤0.01%
+174
New +$632
XYLO
142
DELISTED
Xylo Technologies
XYLO
$48K ﹤0.01%
231
-1,382
-86% -$427K
ACHN
143
DELISTED
Achillion Pharmaceuticals
ACHN
$48K ﹤0.01%
+16,705
New +$60.7K
CSCI
144
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$46K ﹤0.01%
+3
New +$625
NSPRZ
145
DELISTED
InspireMD, Inc. Series B Warrants
NSPRZ
$40K ﹤0.01%
2,003,848
+1,200
+0.1% +$33
AGEN
146
PUT
Agenus
AGEN
$310M
$38K ﹤0.01%
+6
New +$458
NSPRW
147
DELISTED
InspireMD, Inc. Warrants
NSPRW
$36K ﹤0.01%
1,193,470
-852
-0.1% -$28
BNTCW
148
DELISTED
Benitec Biopharma Limited
BNTCW
$36K ﹤0.01%
90,193
– –
CFRX
149
DELISTED
ContraFect Corporation
CFRX
$35K ﹤0.01%
43
-106
-71% -$87.6K
IMMP
150
Immutep
IMMP
$49.7M
$34K ﹤0.01%
+21,500
New +$41.7K
4 5
6
7 8

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sabby Management held 227 positions worth $1.1B, down 28% from $1.53B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management deployed $36.5M of net new capital in Q4 2017, opening 63 new positions and adding to 36 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.

By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 92% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $3.2M trimmed.

  • Sabby Management's largest Q4 2017 buy was Odonate Therapeutics, Inc. Common Stock: 825,451 shares worth $20.6M.
  • Sabby Management added most to Esperion Therapeutics in Q4 2017, an estimated $3.17M increase.
  • Sabby Management's biggest Q4 2017 reduction was Bristol-Myers Squibb, cutting an estimated $3.2M.
  • Sabby Management fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2017, selling an estimated $3.35M.
  • Sabby Management's ten largest holdings make up 66% of its $1.1B portfolio in Q4 2017.
  • Sabby Management opened 63 new positions and closed 66 in Q4 2017.
  • Sabby Management's portfolio value fell 28% quarter-over-quarter to $1.1B.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.